SEC Comment Letter for Chemomab Therapeutics Ltd. (CMMB) (CIK 0001534248) (CMMB) — Apr 6, 2020
Chemomab Therapeutics Ltd. (CMMB) (CIK 0001534248)
Date: April 6, 2020 · CIK: 0001534248 · Accession: 0000000000-20-002942
AI Filing Summary & Sentiment
File numbers found in text: 001-38807
Letter
April 3, 2020 Frank Haluska Chief Executive Officer Anchiano Therapeutics Ltd. 5 Kiryat Hamada St. P.O. Box 45032 Jerusalem, 9777401, Israel Re:Anchiano Therapeutics Ltd. Preliminary Proxy Statement on Schedule 14A Filed March 30, 2020 File No. 001-38807 Dear Dr. Haluska: We have reviewed your filing and have the following comment. Please respond to the comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to the comment, we may have additional comments. Preliminary Proxy Statement on Schedule 14A Proposal 3: Approval of Amendments to Articles of Association, page 21 1.Please revise the proxy statement to indicate whether you currently have any plans, arrangements or understandings, written or oral, to issue any of the authorized but unissued shares that would become available as a result of the amendment to the Articles of Association. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
FirstName LastNameFrank Haluska Comapany NameAnchiano Therapeutics Ltd. April 3, 2020 Page 2 FirstName LastName Frank Haluska Anchiano Therapeutics Ltd. April 3, 2020 Page 2 Please contact Chris Edwards at (202) 551-6761 or Mary Beth Breslin at (202) 551-3625 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Anna T. Pinedo
Show Raw Text
April 3, 2020
Frank Haluska
Chief Executive Officer
Anchiano Therapeutics Ltd.
5 Kiryat Hamada St.
P.O. Box 45032
Jerusalem, 9777401, Israel
Re:Anchiano Therapeutics Ltd.
Preliminary Proxy Statement on Schedule 14A
Filed March 30, 2020
File No. 001-38807
Dear Dr. Haluska:
We have reviewed your filing and have the following comment.
Please respond to the comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to the comment, we may have additional comments.
Preliminary Proxy Statement on Schedule 14A
Proposal 3: Approval of Amendments to Articles of Association, page 21
1.Please revise the proxy statement to indicate whether you currently have any
plans, arrangements or understandings, written or oral, to issue any of the authorized
but unissued shares that would become available as a result of the amendment to the
Articles of Association.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
FirstName LastNameFrank Haluska
Comapany NameAnchiano Therapeutics Ltd.
April 3, 2020 Page 2
FirstName LastName
Frank Haluska
Anchiano Therapeutics Ltd.
April 3, 2020
Page 2
Please contact Chris Edwards at (202) 551-6761 or Mary Beth Breslin at (202) 551-3625
with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Anna T. Pinedo